Off-label biologic use raises cost and safety concerns Rheumatology Update The study of Australian public hospitals over a six-month period found the monoclonal antibody rituximab was prescribed 364 times for 63 conditions that were not approved under the TGA. The spectrum of clinical conditions involved multiple medical ... |
